FDA approves Shire product for Gaucher disease

Monday 1 March 2010

The US Food and Drug Administration has approved Shire Plc’s treatment for Gaucher disease, Vpriv (velaglucerase alfa), under a special procedure where the review was completed in six months rather than the usual 10.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

United States